Module 07 showed how a company's value gets divided among shareholders. This module asks the prior question: where does the value come from in the first place? The honest answer is that venture valuation is closer to a negotiated number than a calculated one — but there are real methods, real anchors, and real reasons valuations move the way they do. This module covers the methods venture investors actually use, why they mostly rationalize a negotiation rather than determine one, and what the 2021 peak and the 2022-23 crash revealed about what really drives venture valuations.
In a traditional corporate-finance course, you value a company by discounting its future cash flows to present value (DCF). You forecast the cash the business will generate, pick a discount rate that reflects the risk, and the present value of those cash flows is what the company is worth. The method is rigorous, defensible, and — for a mature company with predictable cash flows — reasonably accurate.
For an early-stage startup, this method is almost useless. Consider why:
Mature-company valuation answers "what are this company's future cash flows worth today?" — a calculation. Venture valuation answers "what price will let this investment return the fund if the company succeeds, and what will the founder accept?" — a negotiation anchored to weak signals. The methods in this module are real and useful, but they mostly serve to frame and justify a negotiated number, not to compute an objective one. Understanding this honestly is more useful than pretending venture valuation is a precise science.
This doesn't mean venture valuation is arbitrary. There are anchors — comparable deals, the company's traction, the fund's return math, the state of the market — that constrain where a valuation can land. The methods in this module are the tools investors use to triangulate within those constraints. But a student who leaves this module believing venture valuation is a precise calculation has learned the wrong lesson. The right lesson is that it's a disciplined negotiation, informed by methods but ultimately settled by supply, demand, and leverage.
The most widely taught venture-valuation method works backward from the exit. Rather than forecasting cash flows, it asks: if this company succeeds and exits at some value, and the investor needs a certain return, what valuation today makes the math work? This is the "VC method," and it directly reflects the fund-returner logic from Module 10.
The logic runs in four steps: (1) estimate the company's exit value if it succeeds; (2) determine the multiple the investor needs to make on this investment; (3) divide to find the maximum post-money valuation today that delivers that multiple; (4) the investor's check size and ownership follow. The method makes the investor's return requirement explicit, which is why it reflects the fund math so directly.
Suppose an investor is considering a seed investment in a company they believe could exit at $500M if it succeeds. The investor wants a 20× return on this investment (high, because most seed investments fail — the winners must carry the losers). Walk through the math:
So the VC method says: to make a $2M investment return 20× at a $500M exit, accounting for future dilution, the investor needs to buy at roughly a $12.5M post-money valuation today. If the founder is asking for $20M post-money, the investor's return math doesn't work and they'll either negotiate the valuation down or pass. If the founder will accept $10M, the investor has a margin of safety.
The VC method doesn't tell you what a company is "worth." It tells you the maximum price an investor can pay and still hit their return target, given their beliefs about the exit and the dilution path. It's a discipline that connects the entry valuation to the fund math (Module 10's fund-returner test). Notice how much it depends on assumptions: the exit value, the required multiple, and the dilution estimate are all judgment calls, and small changes in any of them swing the implied valuation widely. This is the method's honest limitation — it's rigorous given its inputs, but the inputs are guesses.
In practice, the method venture investors use most is the simplest: comparison to other recent deals. What have similar companies, at similar stages, in similar sectors, raised at recently? The comparable deals set the market, and a specific company's valuation lands somewhere in the range that comparables define, adjusted for how the company stacks up against them.
For companies with revenue, the most common form is a revenue multiple: if comparable SaaS companies are raising at 15× ARR, a company with $4M ARR is worth roughly $60M, adjusted up or down for growth rate, margins, market size, and team quality. For pre-revenue companies, comparables are cruder — "seed rounds in this sector are pricing at $8-15M post-money right now" — and the specific company lands within that range based on traction and quality signals.
Revenue multiples vary enormously by stage, because earlier-stage companies are priced more on growth and potential than on current revenue. A useful (if rough) mental model of how multiples compress as companies mature:
| Stage | Typical ARR multiple | What drives the multiple |
|---|---|---|
| Seed (pre-revenue) | n/a | Team, market, narrative; priced by stage benchmark not multiple |
| Series A | 20-40× | Growth rate dominates; revenue small so multiple high |
| Series B | 12-25× | Growth + early efficiency signals |
| Series C+ | 8-15× | Growth + margins + path to profitability |
| Public SaaS | 5-12× | Predictable growth, profitability, public-market discipline |
(These ranges are illustrative and move dramatically with the market — in 2021 they were roughly double these levels; in the 2022-23 trough, lower.) The key insight: the same $10M of ARR is worth wildly different amounts depending on the company's stage and growth rate. A Series A company growing 300% might command a 35× multiple ($350M); a slow-growing Series C company might get 8× ($80M) on the same revenue. Growth rate is the single biggest driver of the multiple at early stages.
For the earliest companies — pre-revenue, sometimes pre-product — even comparables are thin. A set of structured scoring methods emerged to bring some discipline to pricing companies that have essentially no financials. These methods are more checklists than calculations, but they impose useful structure on what would otherwise be pure intuition.
Developed by angel investor Dave Berkus, this method assigns a dollar value (capped at some amount, often ~$500K each) to each of several qualitative achievements: a sound business idea, a working prototype, a quality management team, strategic relationships, and product rollout or early sales. Summing them gives a pre-money valuation, typically capping the method around $2-2.5M. It's crude by design — meant for pre-revenue companies where nothing else applies — but it forces an investor to articulate why a company is worth what they're paying.
The Scorecard method (also called the Bill Payne method) starts with the average pre-money valuation for comparable seed deals in the region and sector, then adjusts up or down based on weighted factors: strength of the team (often weighted most heavily), size of the opportunity, product/technology, competitive environment, marketing/sales, and need for additional funding. A company that scores above average on the heavily-weighted factors gets a premium to the regional average; one that scores below gets a discount.
This method starts from a baseline (often a regional comparable) and adjusts up or down across a list of risk categories — management risk, stage risk, regulatory risk, competitive risk, technology risk, funding risk, and others. Each risk is scored from very negative to very positive, with a corresponding dollar adjustment. The summed adjustments modify the baseline. Like the others, it's a structured way to convert qualitative judgment into a number.
None of these methods is precise, and experienced early-stage investors often don't use them formally at all — they price from gut and market knowledge. But the methods have real pedagogical and practical value: they force the investor to decompose a vague judgment ("this feels like a $5M company") into specific, articulable factors ("strong team, big market, weak competitive moat, high regulatory risk"). That decomposition is useful even when the final number comes from negotiation rather than the formula.
Here is the honest part that most textbooks underplay. The valuation methods in Sections 02-04 are real and worth knowing, but in practice, a venture valuation is determined far more by supply, demand, and leverage than by any method. The methods mostly serve to justify, frame, and sanity-check a number that's actually set by negotiation.
Consider what actually moves a real seed or Series A valuation:
A venture valuation is a negotiated price set by supply, demand, leverage, and market conditions, with the valuation methods serving to frame and justify the negotiation rather than determine it. An experienced investor uses the VC method to check whether a price lets their fund math work, uses comparables to understand the market range, and uses scoring methods to decompose their qualitative judgment — but the actual number comes from the negotiation. This is not a flaw in the methods; it's the nature of pricing assets whose value is fundamentally uncertain. The methods impose discipline on a negotiation; they don't replace it.
This honesty matters for both founders and investors. A founder who believes valuation is a precise calculation will be confused when two investors offer wildly different numbers for the same company; a founder who understands it's a negotiation will focus on building leverage (multiple interested investors) rather than perfecting a valuation spreadsheet. An investor who treats the methods as oracles will overpay in hot markets (when the comparables are inflated) and miss deals in cold ones; an investor who understands the methods as framing tools will use them to maintain discipline when the market loses its head.
There's a second valuation that runs alongside the headline round valuation, and it's a source of constant confusion: the value of the company's common stock, which is almost always much lower than the price investors pay for preferred stock. Understanding why requires connecting back to Module 05 (preferred vs common) and Module 07 (the preference waterfall).
Recall that preferred stock has rights common stock lacks — the liquidation preference (gets paid first), and various protections. Because preferred is senior to common in the waterfall, a share of preferred is genuinely worth more than a share of common at any given total company value. So when an investor pays, say, $10/share for preferred at a Series A, the common stock is simultaneously worth considerably less per share — often 20-40% of the preferred price at early stages, narrowing as the company matures and the preference becomes a smaller part of the total value.
In the U.S., section 409A of the tax code requires companies to obtain an independent valuation of their common stock before granting stock options, to set a defensible strike price. The "409A valuation" is performed by independent appraisers using option-pricing models that account for the preference stack, the probability of different exit scenarios, and the company's stage. The 409A common-stock value is typically well below the latest preferred-round price — which is what lets companies grant options with low strike prices (good for employees) while having just raised at a high preferred valuation.
Allocating a company's total value across multiple share classes — common, and several series of preferred each with different preferences — is genuinely complex. The standard approach treats each share class as a kind of option on the company's exit value: common stock, for instance, is like a call option that only pays off once all the preferences above it have been satisfied (the "preference cliff" from Module 07). Valuing these option-like claims requires option-pricing models (typically the Black-Scholes-based "option pricing method" or more complex scenario-based models). This is mathematically involved enough that specialized software exists to do it.
The clearest demonstration that venture valuations are driven by macro conditions more than by method came in the 2021-2023 cycle — one of the most dramatic valuation round-trips in venture history. Understanding what happened reinforces the central lesson of this module.
Between mid-2020 and late 2021, venture valuations rose to historic highs across every stage. The drivers were macro, not company-specific: near-zero interest rates made risky long-duration assets (like startups) relatively more attractive; enormous amounts of capital flooded into venture (from crossover funds, sovereign wealth, and a fundraising boom); and a self-reinforcing momentum took hold where rising valuations justified more rising valuations (the comparables circularity from Section 03). Seed rounds that would have priced at $8-12M post-money priced at $20-40M; growth rounds reached multiples that bore little relation to fundamentals. The valuation methods didn't change — the market did.
When the Federal Reserve raised interest rates sharply in 2022 to combat inflation, the entire structure reversed. Higher rates made safe assets more attractive and long-duration risky assets less so; public-market tech multiples compressed sharply; the capital flood reversed; and the momentum that had driven valuations up now drove them down. Late-stage valuations fell hardest (Klarna's 85% markdown from Module 02 being the iconic example), and the down rounds and flat rounds that had been rare in 2021 became common. Again, the methods didn't change — the macro environment did, and it dominated everything.
The single clearest lesson of the 2021-2023 cycle is that venture valuations are driven more by macro conditions — interest rates, capital availability, market sentiment — than by any company-specific valuation method. The same company, with the same fundamentals, was worth 2-3× more in 2021 than in 2023. No valuation method predicted or explained this; only the macro environment did. For students, this is the reinforcement of Section 05's point: valuation is a negotiated price set by market conditions, and the methods are framing tools that operate within whatever range the macro environment allows. An investor who maintained method-discipline through 2021 (refusing to pay inflated comparable-based prices) preserved capital for the better deals available in 2023.
To bring the methods together, value Pipework's Series A using two methods and see where they land relative to the $75M post-money the company actually raised at (from Modules 02 and 07). Pipework at Series A: $2M ARR, growing 200% year-over-year, strong team, large market, in a competitive but not crowded space.
| Method | Implied post-money | What drives it |
|---|---|---|
| Comparables | $60-80M | Market multiple for the growth profile |
| VC method | $75M | Lead's return math at a $1.5B exit belief |
| Actual raise | $75M | Negotiated within the methods' range |
The two methods produce overlapping ranges, and the actual $75M raise sits comfortably within them. This is what good practice looks like: the methods don't dictate the number, but they define a defensible range, and the negotiated price lands inside it. Had the founder pushed for $150M, both methods would have flagged it as outside the defensible range (the comparables would say 75× ARR is unjustifiable; the VC method would say the lead's return math breaks). Had the investor pushed for $40M, the founder's leverage (200% growth, presumably multiple interested investors) would have pulled it back up.
In practice, the $75M was set by the dynamics from Section 05, not the methods: Pipework's strong growth attracted multiple term sheets, giving the founders leverage; the lead investor's fund math (the VC method) set their ceiling at around $75M; the comparables gave both sides a shared reference for what "market" looked like; and the final number landed where the founders' leverage met the lead's return discipline. The methods framed the negotiation and kept it disciplined; the negotiation set the price.
Venture valuation is a negotiated price, framed and disciplined by methods (the VC method connecting to fund math, comparables defining the market range, scoring methods decomposing early-stage judgment), set within a range that macro conditions allow, and ultimately determined by supply, demand, and leverage. The methods matter — they keep the negotiation honest and connected to the fund math — but they don't replace the negotiation. A student who understands this can read any venture valuation correctly: as a number that reflects the company's quality, the market environment, and the relative leverage of the parties, all at once.
Six questions on venture valuation methods, the honest reality of negotiation, the common-vs-preferred valuation gap, and the macro-over-method lesson.